Detalhe da pesquisa
1.
Medicine donations: a review of policies and practices.
Global Health
; 19(1): 67, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37658389
2.
Corruption risks in health procurement during the COVID-19 pandemic and anti-corruption, transparency and accountability (ACTA) mechanisms to reduce these risks: a rapid review.
Global Health
; 19(1): 91, 2023 Nov 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38001483
3.
Disclosure, transparency, and accountability: a qualitative survey of public sector pharmaceutical committee conflict of interest policies in the World Health Organization South-East Asia Region.
Global Health
; 18(1): 33, 2022 03 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35303902
4.
The Global Fund: why anti-corruption, transparency and accountability matter.
Global Health
; 17(1): 108, 2021 09 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34537059
5.
Intellectual property and access to medicines: mapping public attitudes toward pharmaceuticals during the United States-Mexico-Canada Agreement (USMCA) negotiation process.
Global Health
; 17(1): 92, 2021 08 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34416883
6.
Exploring anti-corruption, transparency, and accountability in the World Health Organization, the United Nations Development Programme, the World Bank Group, and the Global Fund to Fight AIDS, Tuberculosis and Malaria.
Global Health
; 16(1): 101, 2020 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33081805
7.
Social capital and public health: responding to the COVID-19 pandemic.
Global Health
; 16(1): 88, 2020 09 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32977805
8.
Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts.
Global Health
; 15(Suppl 1): 78, 2019 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31775767
9.
The sustainable development goals as a framework to combat health-sector corruption.
Bull World Health Organ
; 96(9): 634-643, 2018 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30262945
10.
Increasing transparency and accountability in national pharmaceutical systems.
Bull World Health Organ
; 96(11): 782-791, 2018 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30455533
11.
Matching safety to access: global actors and pharmacogovernance in Kenya- a case study.
Global Health
; 13(1): 20, 2017 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28335786
12.
Corporate social responsibility to improve access to medicines: the case of Brazil.
Global Health
; 13(1): 10, 2017 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-28222793
13.
The disease of corruption: views on how to fight corruption to advance 21st century global health goals.
BMC Med
; 14(1): 149, 2016 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-27680102
14.
Civil society participation in the health system: the case of Brazil's Health Councils.
Global Health
; 12(1): 64, 2016 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27782831
15.
Why the COVID-19 pandemic should be a call for action to advance equitable access to medicines.
BMC Med
; 18(1): 193, 2020 Jun 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32586387
16.
Participatory health councils and good governance: healthy democracy in Brazil?
Int J Equity Health
; 14: 21, 2015 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-25889170
17.
Does Pharmaceutical Pricing Transparency Matter? Examining Brazil's Public Procurement System.
Global Health
; 11: 34, 2015 Aug 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-26238110
18.
"To patent or not to patent? the case of Novartis' cancer drug Glivec in India".
Global Health
; 10: 3, 2014 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-24393270
19.
A call for a moratorium on the .health generic top-level domain: preventing the commercialization and exclusive control of online health information.
Global Health
; 10: 62, 2014 Sep 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-25283176
20.
Why the MDGs need good governance in pharmaceutical systems to promote global health.
BMC Public Health
; 14: 63, 2014 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-24447600